CRIS Current Research Information System

CATANI, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.214
AS - Asia 3.716
EU - Europa 3.367
SA - Sud America 342
AF - Africa 262
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 12.911
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.147
SG - Singapore 1.263
CN - Cina 934
GB - Regno Unito 769
VN - Vietnam 699
IT - Italia 644
SE - Svezia 557
DE - Germania 438
HK - Hong Kong 346
BR - Brasile 269
IN - India 222
IE - Irlanda 167
RU - Federazione Russa 163
FR - Francia 142
NL - Olanda 88
TG - Togo 74
UA - Ucraina 72
FI - Finlandia 71
ZA - Sudafrica 66
CI - Costa d'Avorio 63
EE - Estonia 59
BG - Bulgaria 51
KR - Corea 50
JO - Giordania 46
CA - Canada 44
CH - Svizzera 42
BE - Belgio 36
JP - Giappone 28
TR - Turchia 27
AR - Argentina 24
NG - Nigeria 24
IR - Iran 21
ID - Indonesia 20
EC - Ecuador 18
BD - Bangladesh 13
MX - Messico 13
SC - Seychelles 13
AT - Austria 12
PL - Polonia 12
MY - Malesia 11
ES - Italia 9
CO - Colombia 8
LT - Lituania 8
AU - Australia 7
TW - Taiwan 6
CL - Cile 5
CZ - Repubblica Ceca 5
GR - Grecia 5
PY - Paraguay 5
RO - Romania 5
VE - Venezuela 5
IQ - Iraq 4
MA - Marocco 4
PE - Perù 4
DZ - Algeria 3
EG - Egitto 3
LB - Libano 3
TH - Thailandia 3
TN - Tunisia 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BO - Bolivia 2
CR - Costa Rica 2
GH - Ghana 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
HU - Ungheria 2
IL - Israele 2
KE - Kenya 2
KG - Kirghizistan 2
LV - Lettonia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
SN - Senegal 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BB - Barbados 1
CY - Cipro 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
JM - Giamaica 1
KZ - Kazakistan 1
MK - Macedonia 1
NP - Nepal 1
PH - Filippine 1
PS - Palestinian Territory 1
PT - Portogallo 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TT - Trinidad e Tobago 1
YT - Mayotte 1
Totale 12.911
Salva come PNG Salva come JPEG
Città #
Singapore 807
Southend 663
Ashburn 638
Fairfield 535
Chandler 524
Hong Kong 342
Dong Ket 263
Woodbridge 237
Seattle 229
Houston 228
Wilmington 220
Cambridge 216
Ann Arbor 195
Santa Clara 184
Beijing 173
Princeton 171
Dublin 166
Boardman 149
Bologna 126
Ho Chi Minh City 115
Hefei 93
Dallas 79
Los Angeles 78
Hanoi 76
Lomé 74
Nanjing 68
Milan 67
Westminster 66
Abidjan 63
New York 60
Padova 56
Bremen 54
Helsinki 51
Redmond 50
Sofia 50
Seoul 49
Jinan 47
Amman 46
Munich 46
Shenyang 42
Turin 42
Berlin 40
Brussels 36
Bern 33
Cornaredo 32
Hyderabad 32
Redondo Beach 32
Buffalo 31
San Diego 31
Saint Petersburg 30
Florence 28
Tokyo 27
São Paulo 26
Jacksonville 24
Abeokuta 21
Zhengzhou 21
Medford 20
Guangzhou 19
Frankfurt am Main 18
Nanchang 18
Burdur 17
Changsha 17
Redwood City 17
Toronto 17
Falls Church 16
Hebei 16
Shanghai 16
London 15
Hangzhou 14
Norwalk 14
Taiyuan 14
Turku 14
Tianjin 13
Chicago 12
Fremont 12
Rome 12
San Francisco 12
Boston 11
Dearborn 11
Des Moines 11
Jakarta 11
Stockholm 11
Bengaluru 10
Brooklyn 10
Orem 10
Quận Bình Thạnh 10
Boydton 9
Bühl 9
Kuala Lumpur 9
Monheim 9
Ningbo 9
Perugia 9
Pune 9
Biên Hòa 8
Castel Maggiore 8
Da Nang 8
Falkenstein 8
Haiphong 8
Jiaxing 8
Kunming 8
Totale 8.419
Salva come PNG Salva come JPEG
Nome #
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 284
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 226
A novel model of CCl4-induced cirrosi with ascites in the mouse. 207
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 205
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 203
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 197
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 195
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 187
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 186
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 186
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 185
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 181
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 176
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 174
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 173
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 172
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 170
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 170
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 169
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 169
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 167
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 165
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 164
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 162
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 160
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 159
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 158
Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating ability 156
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy 155
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 154
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling 152
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 152
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function 151
Molecular and functional characterization of CD133+stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 151
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 150
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 148
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 147
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 147
SuperB: A High-Luminosity Asymmetric e+ e- Super Flavor Factory. Conceptual Design Report 145
Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia 144
Stem cell mobilization and collection in patients with liver cirrhosis. 144
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling 144
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 142
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 141
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: a phase I clinical trial 141
Increased transcription of mitochondrial genes for Complex I in human platelets during ageing 139
Platelet lysate enhances the therapeutic activity of Adipose Derived Mesenchymal stromal cells isolated from Crohn disease patients in a novel Mouse model of Colitis 138
CD 133+ stem cells for the treatment of end stage liver disease. 137
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 132
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 129
The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engrftment. 127
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 125
The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis 123
The “vesicular intelligence” strategy of blood cancers 123
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 122
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS). 121
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency 120
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. 119
INFLAMMATORY PATHWAYS IN THE BONE MARROW: ROLE OF TIMP-1 IN HEMATOPOIETIC STEM/PROGENITOR CELLS AND LEUKEMIA 118
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 116
Partial splenic embolization preceding splenectomy, in a case of refractory immune thrombocytopenic purpura. 115
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms 114
Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product 113
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study 112
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 111
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 109
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge 108
null 107
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 105
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 105
The CD47 pathway is deregulated in human immune thrombocytopenia 103
Low-dose methotrexate as treatment of myeloproliferative neoplasms: Proof of principle of clinical activity 99
null 98
null 96
CD133+ stem cells for the treatment of end-stage liver disease 92
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 92
null 86
CD133+ hematopoietic stem cells reinfusion in end-stage liver disease (ESLD): final results of a phase I clinical trial 86
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients 85
SPONTANEOUS MOBILIZATIONOF BONE MARROW-DERIVED HEMATOPOIETIC AND ENDOTHELAIL PROGENITOR CELLS AFTER ORTHOTOPIC LIVER TRANSPALNTATION (OLT). 81
Human T-lymphocyte-derived megakaryocyte colony-stimulating activity 79
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia 75
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 73
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 72
The power of extracellular vesicles in myeloproliferative neoplasms: “Crafting” a microenvironment that matters 71
null 68
Reinfusion of highly purified CD133+ stem cells in patients with end-stage liver disease (ESLD): final results of a phase I clinical trial 68
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis 67
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years 66
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 66
Is there a gender effect in polycythemia vera? 53
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation 47
Single-Cell Metabolic Profiling Integrated with Extracellular Vesicle Analysis Reveals Novel Metabolic Vulnerabilities and Prognostic Biomarkers in Acute Myeloid Leukemia 45
Increased P-selectin plasma levels in patients with thrombotic thrombocytopenic purpura 37
A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase 36
Cancer procoagulant in acute non lymphoid leukemia: Relationship of enzyme detection to disease activity 34
Ticlopidine in the treatment of thrombotic thrombocytopenic purpura: Report of two cases 33
Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides 28
Procoagulant cellular activity (PCA) in the classification of acute leukemia 25
Prompt plasma-exchange treatment and coma reversibility in two patients with thrombotic thrombocytopenic purpura 23
Totale 12.586
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.866
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.866
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021842 0 0 0 0 0 51 33 62 124 68 48 456
2021/20221.829 118 92 91 194 140 68 48 125 60 203 378 312
2022/20232.094 210 293 120 276 121 175 50 157 367 78 143 104
2023/2024601 48 96 41 75 53 126 27 33 15 41 22 24
2024/20252.286 120 265 205 212 340 113 147 80 86 157 106 455
2025/20262.555 489 445 492 338 582 209 0 0 0 0 0 0
Totale 13.225